These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 29103325)

  • 21. Chronic thalamic stimulation for treatment of dystonic paroxysmal nonkinesigenic dyskinesia.
    Loher TJ; Krauss JK; Burgunder JM; Taub E; Siegfried J
    Neurology; 2001 Jan; 56(2):268-70. PubMed ID: 11160971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective Treatment of Paroxysmal Nonkinesigenic Dyskinesia With Oxcarbazepine.
    Kumar A; Szekely A; Jabbari B
    Clin Neuropharmacol; 2016; 39(4):201-5. PubMed ID: 27046658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of disabling paroxysmal nonkinesigenic dyskinesia with deep brain stimulation of the globus pallidus internus.
    van Coller R; Slabbert P; Vaidyanathan J; Schutte C
    Stereotact Funct Neurosurg; 2014; 92(6):388-92. PubMed ID: 25359315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paroxysmal dyskinesias.
    Bhatia KP
    Mov Disord; 2011 May; 26(6):1157-65. PubMed ID: 21626559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation Analysis of MR-1, SLC2A1, and CLCN1 in 28 PRRT2-negative Paroxysmal Kinesigenic Dyskinesia Patients.
    Wang HX; Li HF; Liu GL; Wen XD; Wu ZY
    Chin Med J (Engl); 2016 May; 129(9):1017-21. PubMed ID: 27098784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PRRT2 truncated mutations lead to nonsense-mediated mRNA decay in Paroxysmal Kinesigenic Dyskinesia.
    Wu L; Tang HD; Huang XJ; Zheng L; Liu XL; Wang T; Wang JY; Cao L; Chen SD
    Parkinsonism Relat Disord; 2014 Dec; 20(12):1399-404. PubMed ID: 25457817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paroxysmal movement disorders: An update.
    Méneret A; Roze E
    Rev Neurol (Paris); 2016; 172(8-9):433-445. PubMed ID: 27567459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Moyamoya-induced paroxysmal dyskinesia.
    Gonzalez-Alegre P; Ammache Z; Davis PH; Rodnitzky RL
    Mov Disord; 2003 Sep; 18(9):1051-6. PubMed ID: 14502675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of MR-1, a novel myofibrillogenesis regulator in human muscle.
    Li TB; Liu XH; Feng S; Hu Y; Yang WX; Han Y; Wang YG; Gong LM
    Acta Biochim Biophys Sin (Shanghai); 2004 Jun; 36(6):412-8. PubMed ID: 15188056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice.
    Li HL; She ZG; Li TB; Wang AB; Yang Q; Wei YS; Wang YG; Liu DP
    Hypertension; 2007 Jun; 49(6):1399-408. PubMed ID: 17420335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of recurrent mutations in the myofibrillogenesis regulator 1 gene.
    Djarmati A; Svetel M; Momcilovic D; Kostic V; Klein C
    Arch Neurol; 2005 Oct; 62(10):1641. PubMed ID: 16216955
    [No Abstract]   [Full Text] [Related]  

  • 32. Phenotypic overlap among paroxysmal dyskinesia subtypes: Lesson from a family with PRRT2 gene mutation.
    Wang K; Zhao X; Du Y; He F; Peng G; Luo B
    Brain Dev; 2013 Aug; 35(7):664-6. PubMed ID: 22902309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary paroxysmal dyskinesias.
    Blakeley J; Jankovic J
    Mov Disord; 2002 Jul; 17(4):726-34. PubMed ID: 12210862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classification of involuntary movements in dogs: Paroxysmal dyskinesias.
    Lowrie M; Garosi L
    Vet J; 2017 Feb; 220():65-71. PubMed ID: 28190498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of a human myofibrillogenesis regulator 1 gene in E. coli and its immunogenicity].
    Li TB; Hu Y; Feng S; Zuo ZY; Wang YG
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):42-7. PubMed ID: 15782492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcellular localisation of BAG-1 and its regulation of vitamin D receptor-mediated transactivation and involucrin expression in oral keratinocytes: implications for oral carcinogenesis.
    Lee SS; Crabb SJ; Janghra N; Carlberg C; Williams AC; Cutress RI; Packham G; Hague A
    Exp Cell Res; 2007 Sep; 313(15):3222-38. PubMed ID: 17662274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of myofibrillogenesis regulator-1 predicts poor prognosis for patients with hepatocellular carcinoma after curative hepatectomy.
    Wang C; Xiang H; Si H; Guo D; Sun M
    Int J Clin Exp Pathol; 2015; 8(11):14818-23. PubMed ID: 26823810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rac1-mediated cytoskeleton rearrangements induced by intersectin-1s deficiency promotes lung cancer cell proliferation, migration and metastasis.
    Jeganathan N; Predescu D; Zhang J; Sha F; Bardita C; Patel M; Wood S; Borgia JA; Balk RA; Predescu S
    Mol Cancer; 2016 Sep; 15(1):59. PubMed ID: 27629044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
    Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.